Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.

Holbrook, Reece; Higuera, Lucas; Wherry, Kael; Phay, Dave; Hsieh, Yu-Cheng; Lin, Kuo-Hung; Liu, Yen-Bin

Holbrook, Reece; Higuera, Lucas; Wherry, Kael; Phay, Dave; Hsieh, Yu-Cheng; Lin, Kuo-Hung; Liu, Yen-Bin.

Afiliação

Holbrook R; Medtronic, plc, Dublin, Ireland.
Higuera L; Medtronic, plc, Dublin, Ireland.
Wherry K; Medtronic, plc, Dublin, Ireland.
Phay D; Medtronic, plc, Dublin, Ireland.
Hsieh YC; Department of Cardiology, Taichung Veterans General Hospital and National Yan-Ming University School of Medicine, Taichung, Taiwan.
Lin KH; Department of Cardiology, China Medical Center University Hospital.
Liu YB; Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

PLoS One ; 15(11): e0241697, 2020.

Article em En | MEDLINE | ID: mdl-33211698

Assuntos

Morte Súbita Cardíaca/prevenção & controle; Desfibriladores Implantáveis; Prevenção Primária/métodos; Feminino; Humanos; Masculino; Cadeias de Markov; Anos de Vida Ajustados por Qualidade de Vida; Fatores de Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prevenção Primária / Morte Súbita Cardíaca / Desfibriladores Implantáveis Tipo de estudo: Etiology_studies / Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google